NNZ-2591 Phase 2 Publication
By Lauren Schmitt, PhDJanuary 12, 2026With Neuren's Phase 3 clinical trial for NNZ-2591 now open for enrollment, the recent publication of…
Use this for any post that you want on the home page
By Lauren Schmitt, PhDJanuary 12, 2026With Neuren's Phase 3 clinical trial for NNZ-2591 now open for enrollment, the recent publication of…
Registration is officially open for the 2026 PMSF Family Conference, The Climb We Make Together, Presented by Neuren Pharmaceuticals, and we’re…
By: Lauren Schmitt, PhD, Chief Science Officer, PMSFDate: December 22, 2025 How Families Can Help Protect the Path to New Treatments…
Why Nutrition Matters in Phelan-McDermid Syndrome By: Meagan Hutchinson, Science & Research Administrator, Phelan-McDermid Syndrome FoundationDecember 18, 2025Nutrition plays a critical…
Neuren’s Phase 3 NNZ-2591 Trial for Phelan-McDermid Syndrome is Now Active! by: Lauren Schmitt, PhDDate: December 15, 2025The Phelan-McDermid Syndrome Foundation is…
Updates on the PMS Natural History Study By: Lauren Schmitt, PhD, Chief Science Officer, Phelan-McDermid Syndrome FoundationDecember 11, 2025 What is…
Phelan-McDermid Syndrome Foundation Names Robbie Baker as Chief Executive Officer by: Denise Croden, President, Phelan-McDermid Syndrome FoundationWe are excited to share…
We surpassed our Giving Tuesday match and raised $77K (exact total to be posted later). We ope you feel the appreciation…
Together We Are Mighty: Attending the 2025 NORD Breakthrough Summit By: Meagan Hutchinson This week, I had the privilege of attending…
Driving Research Breakthroughs Funding research, treatments, and cures for Phelan-McDermid SyndromeThe Phelan-McDermid Syndrome Foundation is proud to launch Driving Research Breakthroughs,…